HealthyNCT01805999
Ispaghula and Colonic Water Content
A study testing 7 g Ispaghula in people with Healthy, run by University of Nottingham at 1 site in United Kingdom.
Trial summary
Chronic constipation is a phenomenon which affects nearly 20% of the population worldwide. Bulking agents such as ispaghula are used as treatments, but only half of the patients are satisfied with the treatment. Read more about this study
- Who is it for?
- Ages 18 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Healthy
- What is being tested?
- 7 g Ispaghula
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 15 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- Mar 2013to Mar 2016
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Apparently healthy; free from GI disorders, aged 18 and 65 years of age
- Male or female
- Body mass index (BMI) between 18.0 and 30.0 kg m-2
- Suitable for MRI scanning (eg absence of metal implants, infusion pumps and pacemakers as assessed by the MRI safety questionnaire
- No known gastrointestinal disease
- Not currently smoking
Show all 9Show fewer
- No strenuous exercise greater than 10 hours per week
- No consumption of more than 21 units of alcohol in a typical week
- No reported participation in another nutritional or biomedical trial 3 months before the pre-study examination or during the study.
Who cannot join
- Inability to discontinue medication likely to alter GI transit
- Antibiotics in the 3 weeks before the pre-study examination
- Pre-existing condition making the need for antibiotics likely during the study
- Previous gastrointestinal surgery (excluding cholecystectomy and appendectomy)
- Known inflammatory bowel disease; coeliac disease
- Subjects considered by the investigator unlikely to comply with study protocol
- Regular (>3 times/week) use of Probiotics in the 3 weeks prior to, or during the study
Trial locations and contacts
1 site in 1 country.
United Kingdom1 site
NDD BRU and Sir Peter Mansfield Magnetic Resonance Centre
Nottingham, Nottinghamshire, NG7 2RD
About this study
Official title: Effect of Ispaghula on Colonic Water Content
Chronic constipation is a phenomenon which affects nearly 20% of the population worldwide. Bulking agents such as ispaghula are used as treatments, but only half of the patients are satisfied with the treatment. This highlights a need for better treatment options, which requires a deeper understanding of the gastrointestinal fate of the products. The GI MRI Research group at the University of Nottingham has been developing new, non-invasive magnetic resonance imaging (MRI) techniques to image the gastrointestinal tract. In collaboration with Ironwood Pharmaceuticals, the investigators now want to understand the gastrointestinal fate of an ispaghula treatment, and also to improve the understanding of MRI parameters when they are applied to the colon.
Read the detailed description
The Rome III diagnostic criteria for constipation must include two or more of the following symptoms > 25 % of the time: straining, hard or lumpy stools, sense of incomplete evacuation, sensation of anorectal obstruction/blockage, the use of manual manoeuvres to facilitate defecation and fewer than 3 defecations per week. Treatments include osmotic laxatives such as polyethylene glycol and lactulose, stimulant laxatives such as bisacodyl, secretagogues like sodium docusate, and bulking agents such as psyllium.
A better understanding of the modes of action of these drugs is required, in order to provide better treatment for chronic constipation. This is somewhat challenging; partly because techniques available to study intestinal contents are limited, and some are unpleasant for the patients. The GI MRI group at the University of Nottingham has recently developed a non-invasive, patient friendly MRI technique for studying the colon. The technique allows assessment of colonic volumes, the response to meals, motility of the colon and transit time of ingested meals. This technique has been used to demonstrate the laxative effect of mannitol and its subsequent reversal with loperamide.
Using MRI, water provides a bright image on T2-weighted images in the small bowel, but the signal is rapidly lost once it reaches the colon. Pilot studies suggest that ispaghula; which is highly hygroscopic and can form a 1.5% gel with water, is able to maintain water in a form which produces bright images on T2-weighted scanning of the colon. The GI MRI group now want to confirm this pilot data by performing a placebo controlled trial of ispaghula husk in healthy volunteers, with the aim of further understanding the mode of action of bulking agents and further improve understanding of MRI parameters when applied to the colon. The aims will be achieved by performing a dose-finding mechanistic study in healthy volunteers, assessing their response to a test meal while taking either placebo, or 2 different doses of ispaghula. Stools will be collected, assessed for water content and compared to water content assessed from T2 weighted MRI. The studies will validate the current technique, optimise current MRI parameters and provide insights into the modes of action of ispaghula.
- Conditions
- Healthy
- Being tested
- 7 g Ispaghula, 7 g placebo, 3.5g Ispaghula + 3.5 g placebo
- Keywords
- Ispaghula, Gastrointestinal physiology, Gastrointestinal response to sugars, MRI, gastrointestinal, stomach, small bowel, colon
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
7 g IspaghulaDietary supplement
Also called Metamucil
7 g placeboDietary supplement
3.5g Ispaghula + 3.5 g placeboDietary supplement
| Study group | Role | What they receive |
|---|---|---|
| 7 g Ispaghula | Experimental | Volunteer will take 7 g of ispaghula 3 times daily for one week Receives: Dietary Supplement: 7 g Ispaghula |
| 7 g placebo | Placebo comparator | Volunteer will take 7 g of a placebo 3 times a day for one week Receives: Dietary Supplement: 7 g placebo |
| 3.5g ispaghula + 3.5 g placebo | Active comparator | Volunteers will take 3.5 g of ispaghula with 3.5 g placebo 3 times daily for one week Receives: Dietary Supplement: 3.5g Ispaghula + 3.5 g placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
ascending colon free water content (ACWC)
An assessment of the volume of water in the ascending colon, as obtained from MR images
Measured: 0 - 360 minutes
Secondary outcomes (4)
Ascending, transverse and descending colon volumes
The volumes of each region of the colon will be determined by segmenting MR images
Measured: 0 - 360 minutes
Geometric centres (GC) 24 and 48 hours
The geometric centres of 5 transit marker pills will be determined at 24 and 48 hours after ingestion
Measured: t = 24 hours and t = 48 hours
Small bowel water content
The volume of water in the small bowel will be evaluated from the MR images over the study day
Measured: 0 - 360 minutes
Gastric emptying
The rate of gastric emptying throughout the study day will be determined from MR images
Measured: 0 - 360 minutes
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Mar 2013 (estimated)
- Study startMar 2013
- Primary completionOct 2013
- Study completionMar 2016
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HealthyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 15 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Nottingham
- Sponsor type
- University, hospital or other
- Collaborators
- Ironwood Pharmaceuticals, Inc.
- Responsible party
- Sponsor
- Investigators
- Robin Spiller, MD, FRCP, Study chair, University of NottinghamJeffrey Johnston, MD, FACP, Study director, Ironwood Pharmaceuticals, Inc.Luca Marciani, Laurea, PhD, Principal investigator, University of NottinghamKathryn Murray, PhD, Principal investigator, University of NottinghamGiles Major, MB BChir, Principal investigator, University of NottiinghamChing Lam, MB BCh, Principal investigator, University of NottinghamCaroline Hoad, PhD, Principal investigator, University of NottinghamPenny Gowland, PhD, Principal investigator, University of Nottingham
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01805999
- Sponsor's protocol ID
- H13122012SCS
- Status last verified
- Feb 2017
- First submitted
- 5 Mar 2013
- Last updated
- 23 Feb 2017
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 23 Feb 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of Ispaghula on Colonic Water Content
- ClinicalTrials.gov ID
- NCT01805999
- Acronym / sponsor ID
- H13122012SCS
- Conditions
- Healthy
- Keywords
- Ispaghula, Gastrointestinal physiology, Gastrointestinal response to sugars, MRI, gastrointestinal, stomach, small bowel, colon
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 15 participants (estimated)
- Lead sponsor
- University of NottinghamUniversity, hospital or other
- Collaborators
- Ironwood Pharmaceuticals, Inc.
- Study start
- Mar 2013
- Primary completion
- Oct 2013 (actual)
- Study completion
- Mar 2016 (actual)
- First posted
- 6 Mar 2013 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Chronic constipation is a phenomenon which affects nearly 20% of the population worldwide. Bulking agents such as ispaghula are used as treatments, but only half of the patients are satisfied with the treatment. This highlights a need for better treatment options, which requires a deeper understanding of the gastrointestinal fate of the products. The GI MRI Research group at the University of Nottingham has been developing new, non-invasive magnetic resonance imaging (MRI) techniques to image the gastrointestinal tract. In collaboration with Ironwood Pharmaceuticals, the investigators now want to understand the gastrointestinal fate of an ispaghula treatment, and also to improve the understanding of MRI parameters when they are applied to the colon.
Detailed description
The Rome III diagnostic criteria for constipation must include two or more of the following symptoms > 25 % of the time: straining, hard or lumpy stools, sense of incomplete evacuation, sensation of anorectal obstruction/blockage, the use of manual manoeuvres to facilitate defecation and fewer than 3 defecations per week. Treatments include osmotic laxatives such as polyethylene glycol and lactulose, stimulant laxatives such as bisacodyl, secretagogues like sodium docusate, and bulking agents such as psyllium.
A better understanding of the modes of action of these drugs is required, in order to provide better treatment for chronic constipation. This is somewhat challenging; partly because techniques available to study intestinal contents are limited, and some are unpleasant for the patients. The GI MRI group at the University of Nottingham has recently developed a non-invasive, patient friendly MRI technique for studying the colon. The technique allows assessment of colonic volumes, the response to meals, motility of the colon and transit time of ingested meals. This technique has been used to demonstrate the laxative effect of mannitol and its subsequent reversal with loperamide.
Using MRI, water provides a bright image on T2-weighted images in the small bowel, but the signal is rapidly lost once it reaches the colon. Pilot studies suggest that ispaghula; which is highly hygroscopic and can form a 1.5% gel with water, is able to maintain water in a form which produces bright images on T2-weighted scanning of the colon. The GI MRI group now want to confirm this pilot data by performing a placebo controlled trial of ispaghula husk in healthy volunteers, with the aim of further understanding the mode of action of bulking agents and further improve understanding of MRI parameters when applied to the colon. The aims will be achieved by performing a dose-finding mechanistic study in healthy volunteers, assessing their response to a test meal while taking either placebo, or 2 different doses of ispaghula. Stools will be collected, assessed for water content and compared to water content assessed from T2 weighted MRI. The studies will validate the current technique, optimise current MRI parameters and provide insights into the modes of action of ispaghula.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Double blind (participant, investigator)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| 7 g Ispaghula | Experimental | Dietary Supplement: 7 g IspaghulaVolunteer will take 7 g of ispaghula 3 times daily for one week |
| 7 g placebo | Placebo comparator | Dietary Supplement: 7 g placeboVolunteer will take 7 g of a placebo 3 times a day for one week |
| 3.5g ispaghula + 3.5 g placebo | Active comparator | Dietary Supplement: 3.5g Ispaghula + 3.5 g placeboVolunteers will take 3.5 g of ispaghula with 3.5 g placebo 3 times daily for one week |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (9 listed)
- Apparently healthy; free from GI disorders, aged 18 and 65 years of age
- Male or female
- Body mass index (BMI) between 18.0 and 30.0 kg m-2
- Suitable for MRI scanning (eg absence of metal implants, infusion pumps and pacemakers as assessed by the MRI safety questionnaire
- No known gastrointestinal disease
Key exclusion criteria (7 listed)
- Inability to discontinue medication likely to alter GI transit
- Antibiotics in the 3 weeks before the pre-study examination
- Pre-existing condition making the need for antibiotics likely during the study
- Previous gastrointestinal surgery (excluding cholecystectomy and appendectomy)
- Known inflammatory bowel disease; coeliac disease
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| 7 g IspaghulaAlso: Metamucil | Dietary supplement | 7 g Ispaghula |
| 7 g placebo | Dietary supplement | 7 g placebo |
| 3.5g Ispaghula + 3.5 g placebo | Dietary supplement | 3.5g ispaghula + 3.5 g placebo |
Primary outcome
ascending colon free water content (ACWC)
Time frame: 0 - 360 minutes
An assessment of the volume of water in the ascending colon, as obtained from MR images
4 secondary outcomes
Ascending, transverse and descending colon volumes
Time frame: 0 - 360 minutes
Geometric centres (GC) 24 and 48 hours
Time frame: t = 24 hours and t = 48 hours
Small bowel water content
Time frame: 0 - 360 minutes
Gastric emptying
Time frame: 0 - 360 minutes
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Feb 2017.
Related trials for Healthy
Not yet recruitingPhase 1
Dynamic Magnetic Resonance Imaging of Human Subarachnoid Space Using Intrathecal Gadolinium Contrast
Healthy Volunteers
RecruitingObservational study
Survey to Determine Incarcerated Persons' Views on Surrogate Decision Making
Healthy Volunteers
Active, not recruitingPhase 1
A Study to Learn How Different Amounts of the Study Medicine Called PF-07985631 Are Tolerated and Act in the Body of Healthy Adults
Healthy
Not yet recruitingObservational study
Collection and Distribution of Blood Components From Healthy Donors for In Vitro Research Use
Blood Donors, Apheresis
Recruiting
Metabolic Impact of VLCPUFA-Rich Fish Oil: A Clinical Study on Omega-3 Index Enhancement in Healthy Individuals
Fatty Acids, Omega-3, Fish Oils
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Robin Spiller, MD, FRCP study chair
University of Nottingham
Jeffrey Johnston, MD, FACP study director
Ironwood Pharmaceuticals, Inc.
Luca Marciani, Laurea, PhD principal investigator
University of Nottingham
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing 7 g Ispaghula in people with Healthy, run by University of Nottingham at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 23 Feb 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
ascending colon free water content (ACWC) (time frame: 0 - 360 minutes). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Feb 2017.